World Cancer Research Journal WCRJ 2018; 5 (2): e1078



# LETTER TO THE EDITOR ASSOCIATION BETWEEN STATIN USE AND INCIDENCE OF BREAST CANCER

### A. SAFARI<sup>1</sup>, H. SALEHINIYA<sup>2</sup>, K. ALLAH BAKESHEI<sup>3</sup>, A. MOHAMMADIAN-HAFSHEJANI<sup>4,5</sup>

<sup>1</sup>Gonabad University of Medical Sciences, Gonabad, Iran

<sup>2</sup>Zabol University of Medical Sciences, Zabol, Iran

<sup>3</sup>Department of Social Medicine, School of Public Health, Dezful University of Medical Sciences, Dezful, Iran <sup>4</sup>Department of Epidemiology and Biostatistics, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

<sup>5</sup>Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

#### **KEYWORDS:** Statin, Incidence, Breast Cancer.

**LIST OF ABBREVIATIONS: :** *BC: Breast cancer, CI: Confidence Interval.* 

#### Dear Editor,

Breast cancer (BC) is the most common cancer in women. A total of 252,710 new cases and 40610 deaths from BC occurred in women in the United States in 2017. The risk of BC was 12.5% in the American women's lifetime<sup>1</sup>. The pathway and risk factors for this cancer have not been fully diagnosed. Obesity and overweight, family history of BC, genetic factors, environmental factors, low physical activity, and exposure to chemical are among the diagnosed BC risk factors<sup>2,3</sup>. A lot of studies have been planned to identify substances with a chemopreventive potential against breast cancer. The pharmaceutical group of Statins is widely prescribed in the world with the aim to prevent cardiovascular events and stroke.

The protective effects of Statins have been proven against the onset of some cancers. However, controversial results<sup>4</sup> have been observed in studies on the effects of Statins on the incidence of BC, so that some separate investigations have considered Statins as the protective agents<sup>5,6</sup>, as risk factors7-9 and neutral10. There is not any definitive conclusion on the effects of Statins on the risk of BC. Undoubtedly, the results of meta-analysis studies can be helpful in this regard. Several meta-analysis researches on this field have not found any significant relationship between Statin use and the increase or decrease in the BC risk, so that the relative risk of BC in the treatment group compared to the control group was obtained equal to 0.94 (CI of 95%, 0.86-1.03) in the research by Islam et al<sup>11</sup>, equal to 1.02 (CI: 95%, 0.95-1.09) in research by Qi-Jun et al<sup>12</sup>, equal to 0.99 (CI of 95%, 0.94-1.04) in study by Undela et al<sup>4</sup>, and equal to 1.02 (CI of 95%, 0.89-1.18) in study by Bonova et al<sup>10</sup>. According to a research by Islam et al<sup>11</sup>, the relative risk of BC was equal to 0.94 (CI of 95%, 0.70-1.28) for those who received Statins for 5 years or less and equal to 0.74 (CI of 95%, 0.52-1.04) for those who received Statins for over 5 years<sup>11</sup>.

Furthermore, there was not any significant difference between Statins and the risk of BC in different parts of the world, so that the relative risk of BC in the treatment group compared to the control group was equal to 0.85 (CI of 95%, 0.41-1.52) in Asia, 1.01 (CI of 95%, 0.97-1.05) in Europe, 1.13 (CI of 95%, 0.44-2.92) in Oceania, and 0.92 (CI of 95%, 0.84-1.02) in the United States<sup>11</sup>. Therefore, based on the results of meta-analysis studies, which

## World Cancer Research Journal

provide the highest level of scientific inferences, the use of statin does not significantly increase or decrease the risk of BC in recipients. Furthermore, the incidence of BC does not depend on the duration of Statin use and the geographical area of residence. Consequently, statins can be used in prevention of cardiovascular diseases and stroke without any worry about the increased risk of BC.

#### **CONFLICT OF INTERESTS:**

The Authors declare that they have no conflict of interests.

#### REFERENCES

- 1. SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
- MAJEED W, ASLAM B, JAVED I, KHALIQ T, MUHAMMAD F, ALI A, RAZA A. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev 2014; 15: 3353-3358.
- ROJAS K, STUCKEY A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol 2016; 59: 651-672.
- UNDELA K, SRIKANTH V, BANSAL D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135: 261-269.

- POCOBELLI G, NEWCOMB PA, TRENTHAM-DIETZ A, TITUS-ERNSTOFF L, HAMPTON JM, EGAN KM. Statin use and risk of breast cancer. Cancer 2008; 112: 27-33.
- HAUKKA J, SANKILA R, KLAUKKA T, LONNQVIST J, NISKANEN L, TANSKANEN A, WAHLBECK K, TIIHONEN J. Incidence of cancer and statin usage--record linkage study. Int J Cancer 2010; 126: 279-284.
- BECK P, WYSOWSKI DK, DOWNEY W, BUTLER-JONES D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003; 56: 280-285.
- EATON M, EKLOF J, BEAL JR, SAHMOUN AE. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res 2009; 29: 5143-5148.
- COOGAN PF, ROSENBERG L, PALMER JR, STROM BL, ZAUBER AG, SHAPIRO S. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13: 262-267.
- BONOVAS S, FILIOUSSI K, TSAVARIS N, SITARAS NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23: 8606-8612.
- ISLAM MM, YANG HC, NGUYEN PA, POLY TN, HUANG CW, KEKADE S, KHALFAN AM3, DEBNATH T, LI YJ, ABDUL SS. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 2017; 296: 1043-1053.
- WU QJ, TU C, LI YY, ZHU J, QIAN KQ, LI WJ, WU L. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget 2015; 6: 42988-43004.